Haemonetics Financial Statements From 2010 to 2024

HAE Stock  USD 85.43  0.51  0.60%   
Haemonetics financial statements provide useful quarterly and yearly information to potential Haemonetics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Haemonetics financial statements helps investors assess Haemonetics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Haemonetics' valuation are summarized below:
Gross Profit
530.8 M
Profit Margin
0.091
Market Capitalization
4.3 B
Enterprise Value Revenue
3.8133
Revenue
1.4 B
There are over one hundred nineteen available fundamental trends for Haemonetics, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Haemonetics' regular performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road.

Haemonetics Total Revenue

1.37 Billion

Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics' main balance sheet or income statement drivers, such as Interest Expense of 15.4 M, Total Revenue of 1.4 B or Gross Profit of 710.4 M, as well as many indicators such as Price To Sales Ratio of 4.27, Dividend Yield of 0.0098 or PTB Ratio of 5.13. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.
  
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Haemonetics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding42.5 M51.4 M51.5 M
Slightly volatile
Total Assets2.3 B2.2 B1.5 B
Slightly volatile
Short and Long Term Debt Total848.2 M807.8 M465.7 M
Slightly volatile
Other Current Liabilities194.8 M185.6 M113.7 M
Slightly volatile
Total Current Liabilities161.5 M300.4 M231 M
Slightly volatile
Total Stockholder Equity535.9 M960 M701.5 M
Slightly volatile
Property Plant And Equipment Net185.9 M366.6 M266 M
Slightly volatile
Retained Earnings281.9 M360.5 M271.9 M
Pretty Stable
Accounts Payable77 M73.4 M51.4 M
Slightly volatile
Cash138.4 M178.8 M170.6 M
Slightly volatile
Non Current Assets Total1.5 B1.4 B871.9 M
Slightly volatile
Non Currrent Assets Other99.5 M90.5 M175.2 M
Slightly volatile
Cash And Short Term Investments140.6 M178.8 M170.7 M
Slightly volatile
Net Receivables120.7 M206.6 M150.3 M
Slightly volatile
Liabilities And Stockholders Equity2.3 B2.2 B1.5 B
Slightly volatile
Non Current Liabilities Total982 M935.2 M490.5 M
Slightly volatile
Inventory333.1 M317.2 M216.9 M
Slightly volatile
Other Current Assets40.1 M66.3 M49.7 M
Pretty Stable
Other Stockholder Equity666.4 M634.6 M477.7 M
Slightly volatile
Total Liabilities1.3 B1.2 B731.8 M
Slightly volatile
Property Plant And Equipment GrossB959.2 M446.6 M
Slightly volatile
Total Current Assets437.2 M768.9 M568.2 M
Slightly volatile
Short Term Debt9.7 M10.2 M52.1 M
Pretty Stable
Intangible Assets426.4 M406.1 M231.1 M
Slightly volatile
Common Stock Total Equity421 K579.6 K477.5 K
Slightly volatile
Common Stock419.7 K508 K474.6 K
Slightly volatile
Other Liabilities131.1 M124.9 M58.6 M
Slightly volatile
Other Assets0.951.020.7 M
Pretty Stable
Long Term Debt837.4 M797.6 M416.3 M
Slightly volatile
Good Will593.3 M565.1 M319.2 M
Slightly volatile
Property Plant Equipment213.6 M357.5 M273.5 M
Slightly volatile
Retained Earnings Total Equity230.9 M227.9 M280.8 M
Slightly volatile
Long Term Debt Total910.6 M867.2 M423.3 M
Slightly volatile
Capital Surpluse516.6 M683.9 M487 M
Slightly volatile
Deferred Long Term Liabilities26.4 M41.6 M25.4 M
Slightly volatile
Non Current Liabilities Other55.7 M75 M51 M
Slightly volatile
Deferred Long Term Asset Charges3.3 MM3.5 M
Slightly volatile
Short and Long Term Debt9.7 M10.2 M162.6 M
Slightly volatile
Cash And Equivalents214.1 M327.1 M182.8 M
Slightly volatile
Net Invested Capital1.1 B1.8 BB
Pretty Stable
Net Working Capital400.1 M468.5 M260.1 M
Slightly volatile
Capital Stock406 K508 K502.1 K
Slightly volatile
Capital Lease Obligations6.2 M6.5 M46.1 M
Slightly volatile

Haemonetics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue1.4 B1.3 B933.2 M
Slightly volatile
Gross Profit710.4 M676.5 M457.4 M
Slightly volatile
EBITDA275.2 M262.1 M168.3 M
Slightly volatile
Depreciation And Amortization54.3 M97.2 M80.4 M
Slightly volatile
Other Operating Expenses1.2 B1.1 B813.6 M
Slightly volatile
Cost Of Revenue330.3 M632.5 M458.8 M
Slightly volatile
Total Operating Expenses553 M526.7 M371.6 M
Slightly volatile
Research Development33.3 M54.4 M41.1 M
Pretty Stable
Selling General Administrative235.5 M424.7 M295.6 M
Slightly volatile
Selling And Marketing Expenses4.8 M7.1 M4.4 M
Slightly volatile
Non Recurring630.4 K663.5 K21.7 M
Very volatile
Interest Income13.3 M16.8 M11.6 M
Slightly volatile
Reconciled Depreciation77.9 M97.2 M92.3 M
Pretty Stable

Haemonetics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow121.2 M115.5 M73.9 M
Slightly volatile
Begin Period Cash Flow298.7 M284.5 M182.4 M
Slightly volatile
Depreciation54.3 M97.2 M80.4 M
Slightly volatile
Capital Expenditures54.3 M66.3 M73.9 M
Pretty Stable
Total Cash From Operating Activities107 M181.8 M143.2 M
Slightly volatile
End Period Cash Flow138.4 M178.8 M170.6 M
Slightly volatile
Change To Netincome40.4 M41.6 M38.7 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.273.3063.0274
Slightly volatile
Dividend Yield0.00980.0110.012
Slightly volatile
PTB Ratio5.134.50834.0171
Slightly volatile
Days Sales Outstanding61.0657.595160.6253
Slightly volatile
Book Value Per Share14.2618.931914.6637
Slightly volatile
Free Cash Flow Yield0.03770.02670.0392
Slightly volatile
Operating Cash Flow Per Share4.183.58443.9771
Slightly volatile
Stock Based Compensation To Revenue0.01440.02160.016
Slightly volatile
Capex To Depreciation0.840.6820.9755
Slightly volatile
PB Ratio5.134.50834.0171
Slightly volatile
EV To Sales4.353.78653.3118
Slightly volatile
Free Cash Flow Per Share2.762.27692.3064
Slightly volatile
Inventory Turnover3.061.99412.4739
Slightly volatile
Days Of Inventory On Hand119183151
Slightly volatile
Payables Turnover8.98.62239.828
Slightly volatile
Sales General And Administrative To Revenue0.350.32440.3288
Slightly volatile
Research And Ddevelopement To Revenue0.04340.04160.0434
Slightly volatile
Capex To Revenue0.08270.05060.0866
Pretty Stable
Cash Per Share3.423.55923.8873
Slightly volatile
POCF Ratio17.5223.811514.8755
Slightly volatile
Payout Ratio0.190.220.2344
Slightly volatile
Capex To Operating Cash Flow0.340.36480.4281
Slightly volatile
PFCF Ratio26.5237.484425.8831
Slightly volatile
Days Payables Outstanding41.042.331938.2199
Slightly volatile
EV To Operating Cash Flow17.8527.272216.2881
Slightly volatile
EV To Free Cash Flow27.0242.932328.3285
Slightly volatile
Intangibles To Total Assets0.30.44230.3285
Slightly volatile
Net Debt To EBITDA0.482.39981.9715
Pretty Stable
Current Ratio1.352.55972.6079
Pretty Stable
Receivables Turnover5.986.33736.0652
Slightly volatile
Graham Number16.6531.425720.1985
Slightly volatile
Shareholders Equity Per Share14.2618.931914.6637
Slightly volatile
Debt To Equity0.340.84150.6472
Slightly volatile
Capex Per Share1.421.30751.6707
Slightly volatile
Revenue Per Share17.1325.816619.3053
Slightly volatile
Interest Debt Per Share4.8916.187710.1713
Slightly volatile
Debt To Assets0.210.36790.3123
Slightly volatile
Enterprise Value Over EBITDA25.718.911823.911
Slightly volatile
Short Term Coverage Ratios1.1317.768211.6844
Slightly volatile
Operating Cycle180241212
Pretty Stable
Price Book Value Ratio5.134.50834.0171
Slightly volatile
Days Of Payables Outstanding41.042.331938.2199
Slightly volatile
Dividend Payout Ratio0.190.220.2344
Slightly volatile
Price To Operating Cash Flows Ratio17.5223.811514.8755
Slightly volatile
Price To Free Cash Flows Ratio26.5237.484425.8831
Slightly volatile
Ebt Per Ebit1.060.9211.1159
Slightly volatile
Effective Tax Rate0.240.22590.1426
Slightly volatile
Company Equity Multiplier1.642.28721.9909
Slightly volatile
Long Term Debt To Capitalization0.07320.45380.3403
Slightly volatile
Total Debt To Capitalization0.250.4570.3777
Slightly volatile
Debt Equity Ratio0.340.84150.6472
Slightly volatile
Quick Ratio0.941.50381.7174
Very volatile
Dividend Paid And Capex Coverage Ratio2.952.74152.3625
Slightly volatile
Net Income Per E B T0.760.77410.8578
Slightly volatile
Cash Ratio0.470.59520.8333
Slightly volatile
Cash Conversion Cycle139198174
Pretty Stable
Operating Cash Flow Sales Ratio0.240.13880.2039
Slightly volatile
Days Of Inventory Outstanding119183151
Slightly volatile
Days Of Sales Outstanding61.0657.595160.6253
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.660.63520.5719
Slightly volatile
Cash Flow Coverage Ratios0.870.2250.4666
Slightly volatile
Price To Book Ratio5.134.50834.0171
Slightly volatile
Fixed Asset Turnover2.723.57053.2446
Slightly volatile
Capital Expenditure Coverage Ratio2.952.74152.3625
Slightly volatile
Price Cash Flow Ratio17.5223.811514.8755
Slightly volatile
Enterprise Value Multiple25.718.911823.911
Slightly volatile
Debt Ratio0.210.36790.3123
Slightly volatile
Cash Flow To Debt Ratio0.870.2250.4666
Slightly volatile
Price Sales Ratio4.273.3063.0274
Slightly volatile
Asset Turnover0.730.59620.6693
Slightly volatile
Gross Profit Margin0.460.51680.4837
Slightly volatile
Price Fair Value5.134.50834.0171
Slightly volatile

Haemonetics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B1.9 B
Slightly volatile
Enterprise Value1.5 B1.4 B1.9 B
Slightly volatile

Haemonetics Fundamental Market Drivers

Forward Price Earnings18.4843
Cash And Short Term Investments178.8 M

Haemonetics Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Haemonetics Financial Statements

Haemonetics stakeholders use historical fundamental indicators, such as Haemonetics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Haemonetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Haemonetics' assets and liabilities are reflected in the revenues and expenses on Haemonetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Haemonetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue31.2 M22.5 M
Total Revenue1.3 B1.4 B
Cost Of Revenue632.5 M330.3 M
Stock Based Compensation To Revenue 0.02  0.01 
Sales General And Administrative To Revenue 0.32  0.35 
Research And Ddevelopement To Revenue 0.04  0.04 
Capex To Revenue 0.05  0.08 
Revenue Per Share 25.82  17.13 
Ebit Per Revenue 0.13  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.375
Earnings Share
2.41
Revenue Per Share
26.77
Quarterly Revenue Growth
0.086
Return On Assets
0.0588
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.